1 of 1
Story summary
- The FDA is updating cancer drug trial guidelines to prioritize overall survival instead of tumor shrinkage.
- This change seeks to improve outcomes for cancer patients, especially Black Americans with higher mortality rates.
- Larger, longer studies may slow drug approvals but aim to enhance treatment effectiveness.
- Patient-reported outcomes will be included to promote a comprehensive approach to cancer care.
- The revisions aim to build trust and ensure equitable clinical trial outcomes.
